Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 44
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Molecules ; 28(19)2023 Oct 03.
Artigo em Inglês | MEDLINE | ID: mdl-37836759

RESUMO

Fourteen quinolizidine derivatives, structurally related to the alkaloids lupinine and cytisine and previously studied for other pharmacological purposes, were presently tested for antiarrhythmic, and other cardiovascular effects on isolated guinea pig heart tissues in comparison to well-established reference drugs. According to their structures, the tested compounds are assembled into three subsets: (a) N-(quinolizidinyl-alkyl)-benzamides; (b) 2-(benzotriazol-2-yl)methyl-1-(quinolizidinyl)alkyl-benzimidazoles; (c) N-substituted cytisines. All compounds but two displayed antiarrhythmic activity that was potent for compounds 4, 1, 6, and 5 (in ascending order). The last compound (N-(3,4,5-trimethoxybenzoyl)aminohomolupinane) was outstanding, exhibiting a nanomolar potency (EC50 = 0.017 µM) for the increase in the threshold of ac-arrhythmia. The tested compounds shared strong negative inotropic activity; however, this does not compromise the value of their antiarrhythmic action. On the other hand, only moderate or modest negative chronotropic and vasorelaxant activities were commonly observed. Compound 5, which has high antiarrhythmic potency, a favorable cardiovascular profile, and is devoid of antihypertensive activity in spontaneously hypertensive rats, represents a lead worthy of further investigation.


Assuntos
Alcaloides , Quinolizidinas , Esparteína , Ratos , Animais , Cobaias , Quinolizidinas/farmacologia , Antiarrítmicos/farmacologia , Antiarrítmicos/química , Coração , Esparteína/farmacologia , Arritmias Cardíacas/tratamento farmacológico , Alcaloides/farmacologia
2.
Eur J Med Chem ; 250: 115169, 2023 Mar 15.
Artigo em Inglês | MEDLINE | ID: mdl-36753881

RESUMO

A set of twenty-five thioxanthene-9-one and xanthene-9-one derivatives, that were previously shown to inhibit cholinesterases (ChEs) and amyloid ß (Aß40) aggregation, were evaluated for the inhibition of tau protein aggregation. All compounds exhibited a good activity, and eight of them (5-8, 10, 14, 15 and 20) shared comparable low micromolar inhibitory potency versus Aß40 aggregation and human acetylcholinesterase (AChE), while inhibiting human butyrylcholinesterase (BChE) even at submicromolar concentration. Compound 20 showed outstanding biological data, inhibiting tau protein and Aß40 aggregation with IC50 = 1.8 and 1.3 µM, respectively. Moreover, at 0.1-10 µM it also exhibited neuroprotective activity against tau toxicity induced by okadoic acid in human neuroblastoma SH-SY5Y cells, that was comparable to that of estradiol and PD38. In preliminary toxicity studies, these interesting results for compound 20 are somewhat conflicting with a narrow safety window. However, compound 10, although endowed with a little lower potency for tau and Aß aggregation inhibition additionally demonstrated good inhibition of ChEs and rather low cytotoxicity. Compound 4 is also worth of note for its high potency as hBChE inhibitor (IC50 = 7 nM) and for the three order of magnitude selectivity versus hAChE. Molecular modelling studies were performed to explain the different behavior of compounds 4 and 20 towards hBChE. The observed balance of the inhibitory potencies versus the relevant targets indicates the thioxanthene-9-one derivatives as potential MTDLs for AD therapy, provided that the safety window will be improved by further structural variations, currently under investigation.


Assuntos
Doença de Alzheimer , Neuroblastoma , Humanos , Doença de Alzheimer/tratamento farmacológico , Doença de Alzheimer/metabolismo , Butirilcolinesterase/metabolismo , Peptídeos beta-Amiloides/metabolismo , Acetilcolinesterase/metabolismo , Inibidores da Colinesterase/química , Estrutura Molecular , Relação Estrutura-Atividade , Neuroblastoma/tratamento farmacológico , Desenho de Fármacos , Simulação de Acoplamento Molecular
3.
Molecules ; 29(1)2023 Dec 25.
Artigo em Inglês | MEDLINE | ID: mdl-38202715

RESUMO

By reducing the 2-nitrophenylhydrazone of cyclohexanone with sodium dithionite, an unexpected yellow compound was obtained instead of the corresponding colorless amino derivative. Many years later, the structure of this compound, namely, cyclohexane-3-spiro-3,4-dihydro-1,2,4-benzotriazine, was demonstrated. From that time, the reduction of 2-nitrophenylhydrazones of different kinds of ketones, followed by air oxidation of the initially formed amino compounds, has represented a general way to synthesize a variety of 3,3-disubstituted 3,4-dihydro-1,2,4-benzotriazines. Many derivatives have been obtained so far by a single research group, and most of them have demonstrated interesting pharmacological activities, mainly antihypertensive, anti-inflammatory, and diuretic effects and other activities with lower diffusion. Moreover, 3,3-disubstituted 3,4-dihydro-1,2,4-benzotriazines represent a novel class of ligands for sigma receptors, with nanomolar affinity to the σ1 subtype. This property might promote the development of agents for cardiovascular, neurodegenerative, and proliferative pathologies. The present commentary, by collecting compounds and biological results obtained so far, intends to celebrate the centennial of the discovery of the first member of this class of compounds and to promote further investigation in the field.


Assuntos
Receptores sigma , Anti-Hipertensivos , Difusão , Cetonas , Triazinas/farmacologia
4.
Eur J Med Chem ; 222: 113562, 2021 Oct 15.
Artigo em Inglês | MEDLINE | ID: mdl-34116325

RESUMO

Triple-negative breast cancer (TNBC) is a cancer subtype critically dependent upon excessive activation of Wnt pathway. The anti-mycobacterial drug clofazimine is an efficient inhibitor of canonical Wnt signaling in TNBC, reducing tumor cell proliferation in vitro and in animal models. These properties make clofazimine a candidate to become first targeted therapy against TNBC. In this work, we optimized the clofazimine structure to enhance its water solubility and potency as a Wnt inhibitor. After extensive structure-activity relationships investigations, the riminophenazine 5-(4-(chlorophenyl)-3-((2-(piperazin-1-yl)ethyl)imino)-N-(pyridin-3-yl)-3,5-dihydrophenazin-2-amine (MU17) was identified as the new lead compound for the riminophenazine-based targeted therapy against TNBC and Wnt-dependent cancers. Compared to clofazimine, the water-soluble MU17 displayed a 7-fold improved potency against Wnt signaling in TNBC cells resulting in on-target suppression of tumor growth in a patient-derived mouse model of TNBC. Moreover, allowing the administration of reduced yet effective dosages, MU17 displayed no adverse effects, most notably no clofazimine-related skin coloration.


Assuntos
Clofazimina/farmacologia , Fenazinas/farmacologia , Animais , Linhagem Celular Tumoral , Proliferação de Células/efeitos dos fármacos , Clofazimina/química , Relação Dose-Resposta a Droga , Ensaios de Seleção de Medicamentos Antitumorais , Humanos , Neoplasias Mamárias Experimentais/tratamento farmacológico , Neoplasias Mamárias Experimentais/metabolismo , Neoplasias Mamárias Experimentais/patologia , Camundongos , Camundongos Endogâmicos NOD , Camundongos SCID , Estrutura Molecular , Fenazinas/síntese química , Fenazinas/química , Solubilidade , Relação Estrutura-Atividade , Água/química , Via de Sinalização Wnt/efeitos dos fármacos
5.
Pharmaceuticals (Basel) ; 13(11)2020 Oct 25.
Artigo em Inglês | MEDLINE | ID: mdl-33113777

RESUMO

Leishmaniases are neglected diseases that are endemic in many tropical and sub-tropical Countries. Therapy is based on different classes of drugs which are burdened by severe side effects, occurrence of resistance and high costs, thereby creating the need for more efficacious, safer and inexpensive drugs. Herein, sixteen 9-thioxanthenone derivatives (lucanthone analogues) and four compounds embodying the diarylethene substructure of amitriptyline (amitriptyline analogues) were tested in vitro for activity against Leishmania tropica and L. infantum promastigotes. All compounds were characterized by the presence of a bulky quinolizidinylalkyl moiety. All compounds displayed activity against both species of Leishmania with IC50 values in the low micromolar range, resulting in several fold more potency than miltefosine, comparable to that of lucanthone, and endowed with substantially lower cytotoxicity to Vero-76 cells, for the best of them. Thus, 4-amino-1-(quinolizidinylethyl)aminothioxanthen-9-one (14) and 9-(quinolizidinylmethylidene)fluorene (17), with selectivity index (SI) in the range 16-24, represent promising leads for the development of improved antileishmanial agents. These two compounds also exhibited comparable activity against intramacrophagic amastigotes of L. infantum. Docking studies have suggested that the inhibition of trypanothione reductase (TryR) may be at the basis (eventually besides other mechanisms) of the observed antileishmanial activity. Therefore, these investigated derivatives may deserve further structural improvements and more in-depth biological studies of their mechanisms of action in order to develop more efficient antiparasitic agents.

6.
J Enzyme Inhib Med Chem ; 33(1): 210-226, 2018 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-29233048

RESUMO

Two sets of benzimidazole derivatives were synthesised and tested in vitro for activity against promastigotes of Leishmania tropica and L. infantum. Most of the tested compounds resulted active against both Leishmania species, with IC50 values in the low micromolar/sub-micromolar range. Among the set of 2-(long chain)alkyl benzimidazoles, whose heterocyclic head was quaternised, compound 8 resulted about 100-/200-fold more potent than miltefosine, even if the selectivity index (SI) versus HMEC-1 cells was only moderately improved. In the set of 2-benzyl and 2-phenyl benzimidazoles, bearing a basic side chain in position 1, compound 28 (2-(4-chlorobenzyl)-1-lupinyl-5-trifluoromethylbenzimidazole) was 12-/7-fold more potent than miltefosine, but exhibited a further improved SI. Therefore, compounds 8 and 28 represent interesting hit compounds, susceptible of structural modification to improve their safety profiles.


Assuntos
Antiprotozoários/farmacologia , Benzimidazóis/farmacologia , Leishmania infantum/efeitos dos fármacos , Leishmania tropica/efeitos dos fármacos , Animais , Antiprotozoários/síntese química , Antiprotozoários/química , Benzimidazóis/síntese química , Benzimidazóis/química , Linhagem Celular , Sobrevivência Celular/efeitos dos fármacos , Chlorocebus aethiops , Relação Dose-Resposta a Droga , Humanos , Estrutura Molecular , Testes de Sensibilidade Parasitária , Relação Estrutura-Atividade , Células Vero
7.
J Enzyme Inhib Med Chem ; 32(1): 588-599, 2017 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-28133984

RESUMO

Positive inotropic agents are fundamental in the treatment of heart failure; however, their arrhythmogenic liability and the increased myocardial oxygen demand strongly limit their therapeutic utility. Pursuing our study on cardiovascular activities of lupin alkaloid derivatives, several 2-(4-substituted-phenyl)-2-dehydrosparteines and 2-(4-substituted-phenyl)sparteines were prepared and tested for inotropic and chronotropic activities on isolated guinea pig atria. Four compounds (6b, 6e, 7b, and 7f) exhibited significant inotropism that, at the higher concentrations, was followed by negative inotropism or toxicity. Compound 7e (2-(4-tolyl)sparteine) exhibited a steep dose-depending inotropic activity up to the highest concentration tested (300 µM) with an Emax of 116.5 ± 3.4% of basal force, proving less potent but much more active in comparison to the highest concentrations tested of digoxin and milrinone having Emax of 87.5 ± 3.1% and 52.2 ± 1.1%, respectively. Finally, docking studies suggested that the relevant sparteine derivatives could target the sigma-1 receptor, whose involvement in cardiac activity is well documented.


Assuntos
Cardiotônicos/química , Cardiotônicos/farmacologia , Esparteína/química , Esparteína/farmacologia , Animais , Espectroscopia de Ressonância Magnética Nuclear de Carbono-13 , Avaliação Pré-Clínica de Medicamentos , Cobaias , Técnicas In Vitro , Masculino , Camundongos , Simulação de Acoplamento Molecular , Espectroscopia de Prótons por Ressonância Magnética , Ratos
8.
Bioorg Med Chem ; 23(21): 7024-34, 2015 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-26443549

RESUMO

A library of 64 benzotriazole derivatives (17 of which were [4-(benzotriazol-2-yl)phenoxy]alkanoic acids) were screened for antiviral activity against a panel of twelve DNA and RNA viruses. Twenty-six compounds (12 of which were [4-(benzotriazol-2-yl)phenoxy]alkanoic acids) displayed activity against one or more viruses. CVB-5, RSV, BVDV, Sb-1 and YFV were, in decreasing order, the more frequently and effectively affected viruses; DENV-2, WNV, HIV-1 and Reo-1 were only occasionally and modestly affected, while the remaining viruses were not affected by any of the tested compounds. Worth of note were compounds 33 and 35; the former for the activity against Sb-1 (EC50=7 µM) and the latter for the large spectrum of activity including six viruses with a mean EC50=12 µM. Even more interesting were the alkanoic acids 45-48 and 50-57 for their activity against RSV and/or CVB-5. In particular, compound 56 displayed a potent and selective activity against CVB-5 with EC50=0.15 µM and SI=100, thus representing a valuable hit compound for the development of antiviral agents for the treatment of human pathologies related to this virus.


Assuntos
Antivirais/química , Enterovirus Humano B/fisiologia , Triazóis/química , Animais , Antivirais/síntese química , Antivirais/toxicidade , Linhagem Celular , Sobrevivência Celular/efeitos dos fármacos , Cricetinae , Vírus de DNA/efeitos dos fármacos , Vírus de DNA/fisiologia , Cães , Enterovirus Humano B/efeitos dos fármacos , Humanos , Vírus de RNA/efeitos dos fármacos , Vírus de RNA/fisiologia , Relação Estrutura-Atividade , Triazóis/síntese química , Triazóis/toxicidade , Replicação Viral/efeitos dos fármacos
9.
ChemMedChem ; 10(9): 1570-83, 2015 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-26213237

RESUMO

Chloroquine is commonly used in the treatment and prevention of malaria, but Plasmodium falciparum, the main species responsible for malaria-related deaths, has developed resistance against this drug. Twenty-seven novel chloroquine (CQ) analogues characterized by a side chain terminated with a bulky basic head group, i.e., octahydro-2H-quinolizine and 1,2,3,4,5,6-hexahydro-1,5-methano-8H-pyrido[1,2-a][1,5]diazocin-8-one, were synthesized and tested for activity against D-10 (CQ-susceptible) and W-2 (CQ-resistant) strains of P. falciparum. Most compounds were found to be active against both strains with nanomolar or sub-micromolar IC50 values. Eleven compounds were found to be 2.7- to 13.4-fold more potent than CQ against the W-2 strain; among them, four cytisine derivatives appear to be of particular interest, as they combine high potency with low cytotoxicity against two human cell lines (HMEC-1 and HepG2) along with easier synthetic accessibility. Replacement of the 4-NH group with a sulfur bridge maintained antiplasmodial activity at a lower level, but produced an improvement in the resistance factor. These compounds warrant further investigation as potential drugs for use in the fight against malaria.


Assuntos
Antimaláricos/química , Antimaláricos/farmacologia , Cloroquina/análogos & derivados , Antimaláricos/síntese química , Técnicas de Química Sintética , Cloroquina/química , Resistência a Medicamentos/efeitos dos fármacos , Células Hep G2/efeitos dos fármacos , Humanos , Estrutura Molecular , Testes de Sensibilidade Parasitária , Plasmodium falciparum/efeitos dos fármacos , Relação Estrutura-Atividade
10.
ChemMedChem ; 10(6): 1040-53, 2015 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-25924599

RESUMO

Multitarget therapeutic leads for Alzheimer's disease were designed on the models of compounds capable of maintaining or restoring cell protein homeostasis and of inhibiting ß-amyloid (Aß) oligomerization. Thirty-seven thioxanthen-9-one, xanthen-9-one, naphto- and anthraquinone derivatives were tested for the direct inhibition of Aß(1-40) aggregation and for the inhibition of electric eel acetylcholinesterase (eeAChE) and horse serum butyrylcholinesterase (hsBChE). These compounds are characterized by basic side chains, mainly quinolizidinylalkyl moieties, linked to various bi- and tri-cyclic (hetero)aromatic systems. With very few exceptions, these compounds displayed inhibitory activity on both AChE and BChE and on the spontaneous aggregation of ß-amyloid. In most cases, IC50 values were in the low micromolar and sub-micromolar range, but some compounds even reached nanomolar potency. The time course of amyloid aggregation in the presence of the most active derivative (IC50 =0.84 µM) revealed that these compounds might act as destabilizers of mature fibrils rather than mere inhibitors of fibrillization. Many compounds inhibited one or both cholinesterases and Aß aggregation with similar potency, a fundamental requisite for the possible development of therapeutics exhibiting a multitarget mechanism of action. The described compounds thus represent interesting leads for the development of multitarget AD therapeutics.


Assuntos
Doença de Alzheimer/tratamento farmacológico , Peptídeos beta-Amiloides/antagonistas & inibidores , Inibidores da Colinesterase/uso terapêutico , Quinolizidinas/química , Peptídeos beta-Amiloides/química , Barreira Hematoencefálica , Inibidores da Colinesterase/química , Inibidores da Colinesterase/farmacocinética , Dicroísmo Circular , Humanos , Cinética , Microscopia Eletrônica de Transmissão , Relação Estrutura-Atividade
11.
Bioorg Med Chem ; 23(1): 55-65, 2015 Jan 01.
Artigo em Inglês | MEDLINE | ID: mdl-25497962

RESUMO

A set of novel riminophenazine derivatives has been synthesized and evaluated for in vitro activity against chloroquine-sensitive (CQ-S) and chloroquine-resistant (CQ-R) strains of Plasmodium falciparum and against different species of Leishmania promastigotes. Most of the new compounds inhibited the growth of Leishmania promastigotes as well as CQ-S and CQ-R strains of P. falciparum with IC50 in submicromolar range, resulting in the best cases 1-2 orders of magnitude more potent than the parent compound clofazimine.


Assuntos
Antiprotozoários/química , Antiprotozoários/farmacologia , Clofazimina/análogos & derivados , Clofazimina/farmacologia , Leishmania/efeitos dos fármacos , Plasmodium falciparum/efeitos dos fármacos , Anti-Inflamatórios/farmacologia , Antimaláricos/química , Antimaláricos/farmacologia , Linhagem Celular , Clofazimina/química , Células Endoteliais , Humanos
12.
Bioorg Med Chem ; 22(24): 6837-45, 2014 Dec 15.
Artigo em Inglês | MEDLINE | ID: mdl-25464882

RESUMO

Novel riminophenazine derivatives, characterized by the presence of the basic and cumbersome quinolizidinylalkyl and pyrrolizidinylethyl moieties, have been synthesized and tested (Rema test) against Mycobacterium tuberculosis H37Rv and H37Ra, and six clinical isolates of Mycobacterium avium and Mycobacterium tuberculosis. Most compounds exhibited potent activity against the tested strains, resulting more active than clofazimine, isoniazid and ethambutol. The best compounds (4, 5, 12 and 13) exhibited a MIC in the range 0.82-0.86µM against all strains of Mycobacterium tuberculosis and, with the exception of 4 a MIC around 3.3µM versus M. avium. The corresponding values for clofazimine (CFM) were 1.06 and 4.23µM, respectively. Cytotoxicity was evaluated against three cell lines and compound 4 displayed a selectivity index (SI) versus the human cell line MT-4 comparable with that of CFM (SI=5.23 vs 6.4). Toxicity against mammalian Vero 76 cell line was quite lower with SI=79.


Assuntos
Antituberculosos/química , Fenazinas/química , Animais , Antituberculosos/farmacologia , Antituberculosos/toxicidade , Linhagem Celular , Sobrevivência Celular/efeitos dos fármacos , Chlorocebus aethiops , Humanos , Testes de Sensibilidade Microbiana , Mycobacterium avium/efeitos dos fármacos , Mycobacterium avium/isolamento & purificação , Mycobacterium tuberculosis/efeitos dos fármacos , Mycobacterium tuberculosis/isolamento & purificação , Fenazinas/farmacologia , Fenazinas/toxicidade , Pirrolidinas/química , Quinolizidinas/química , Relação Estrutura-Atividade , Tuberculose/microbiologia , Células Vero
13.
Bioorg Med Chem ; 22(17): 4893-909, 2014 Sep 01.
Artigo em Inglês | MEDLINE | ID: mdl-25082514

RESUMO

A library of eighty-six assorted benzimidazole derivatives was screened for antiviral activity against a panel of ten RNA and DNA viruses. Fifty-two of them displayed different levels of activity against one or more viruses, among which CVB-5, RSV, BVDV and Sb-1 were the most frequently affected. In particular, fourteen compounds exhibited an EC50 in the range 9-17µM (SI from 6 to >11) versus CVB-5, and seven compounds showed an EC50 in the range 5-15µM (SI from 6.7 to ⩾20) against RSV, thus resulting comparable to or more potent than the respective reference drugs (NM108 and ribavirin). Most of these compounds derive from 2-benzylbenzimidazole, but also other molecular scaffolds [as 1-phenylbenzimidazole (2), 2-trifluoromethylbenzimidazole (69), dihydropyrido[3',2':4,5]imidazo[1,2-a][1,4]benzodiazepin-5-one (3), dibenzo[c,e]benzimidazo[1,2-a]azepine (22), and 2-(tetrahydropyran-2-yl)benzimidazole (81, 82 and 86)] are related to interesting levels of activity against these or other viruses (BVDV, Sb-1). Thus, these scaffolds (some of which, so far unexplored), represent valid starting points to develop more efficient agents against pathologies caused by CVB-5, RSV, BVDV and Sb-1 viruses.


Assuntos
Antivirais/farmacologia , Benzimidazóis/farmacologia , Enterovirus/efeitos dos fármacos , Poliovirus/efeitos dos fármacos , Vírus Sinciciais Respiratórios/efeitos dos fármacos , Animais , Antivirais/síntese química , Antivirais/química , Benzimidazóis/síntese química , Benzimidazóis/química , Bovinos , Linhagem Celular , Proliferação de Células/efeitos dos fármacos , Sobrevivência Celular/efeitos dos fármacos , Chlorocebus aethiops , Cricetinae , Relação Dose-Resposta a Droga , Humanos , Testes de Sensibilidade Microbiana , Estrutura Molecular , Relação Estrutura-Atividade , Células Vero , Replicação Viral/efeitos dos fármacos
14.
Psychopharmacology (Berl) ; 231(9): 1975-85, 2014 May.
Artigo em Inglês | MEDLINE | ID: mdl-24311357

RESUMO

RATIONALE: Neuronal nicotinic acetylcholine receptors (nAChRs) play a modulatory role in cognition, and zebrafish provide a preclinical model to study learning and memory. OBJECTIVES: We investigated the effect of nicotine (NIC) and some new cytisine-derived partial agonists (CC4 and CC26) on spatial memory in zebrafish using a rapid assay on T-maze task. The role of α4/α6ß2 and the α7 nAChRs in NIC-induced memory enhancement was evaluated using selective nAChR antagonists. RESULTS: Low and high doses of NIC, cytisine (CYT), CC4 and CC26 respectively improved and worsened the mean running time, showing an inverted U dose-response function. The effective dose (ED50) (×10⁻5 mg/kg) was 0.4 for CC4, 4.5 for CYT, 140 for NIC and 200 for CC26. NIC-induced cognitive enhancement was reduced by the selective nAChR subtype antagonists: methyllycaconitine (MLA) for α7, α-conotoxin (MII) for α6ß2, dihydro-ß-erythroidine (DhßE) for α4ß2, the nonselective antagonist mecamylamine (MEC) and the muscarinic antagonist scopolamine (SCOP), with DhßE being more active than MLA or MII. All the partial agonists blocked the cognitive enhancement. The improvement with the maximal active dose of each partial agonist was blocked by low doses of DhßE (0.001 mg/kg) and MII (0.01 mg/kg). MLA reduced the effects of CC26 and CC4 at doses of 0.01 and 1 mg/kg, respectively, but did not antagonize CYT-induced memory improvement at any of the tested dose. No change in swimming activity was observed. CONCLUSIONS: Our findings demonstrate that zebrafish make a useful model for the rapid screening of the effect of new α4ß2 nAChR compounds on spatial memory.


Assuntos
Colinérgicos/farmacologia , Aprendizagem em Labirinto/fisiologia , Memória/fisiologia , Neurônios/fisiologia , Receptores Nicotínicos/metabolismo , Peixe-Zebra/fisiologia , Aconitina/análogos & derivados , Aconitina/farmacologia , Alcaloides/química , Alcaloides/farmacologia , Animais , Azocinas/química , Azocinas/farmacologia , Conotoxinas/farmacologia , Di-Hidro-beta-Eritroidina/farmacologia , Relação Dose-Resposta a Droga , Aprendizagem em Labirinto/efeitos dos fármacos , Mecamilamina/farmacologia , Memória/efeitos dos fármacos , Antagonistas Muscarínicos/farmacologia , Neurônios/efeitos dos fármacos , Nicotina/farmacologia , Agonistas Nicotínicos/farmacologia , Antagonistas Nicotínicos/química , Antagonistas Nicotínicos/farmacologia , Quinolizinas/química , Quinolizinas/farmacologia , Escopolamina/farmacologia , Natação , Proteínas de Peixe-Zebra/metabolismo
15.
Mol Divers ; 17(3): 409-19, 2013 08.
Artigo em Inglês | MEDLINE | ID: mdl-23585057

RESUMO

Twenty benzimidazole derivatives bearing in position 1 a ([Formula: see text]-tert-amino)alkyl chain (mainly quinolizidin-1-ylmethyl) and in position 2 an aromatic moiety (phenyl, benzyl or benzotriazol-1/2-ylmethyl) were evaluated at the National Cancer Institute (NCI) for anti-proliferative activity against a panel of 60 human cancer cell lines. Four compounds (6, 7, 9 and 10) displayed a large spectrum of activity with [Formula: see text] 10 [Formula: see text] on 24-57 cell lines, while thirteen compounds exhibited sub-micromolar or even nanomolar activity against single cell lines, such as leukemia CCRF-CEM, HL-60 and MOLT-4, CNS cancer SF-268 and, particularly, renal cancer UO-31, sometimes with outstanding selectivity (compounds 5-7, 11, 13 and 18).


Assuntos
Antineoplásicos/farmacologia , Benzimidazóis/farmacologia , Proliferação de Células/efeitos dos fármacos , Quinolizidinas/farmacologia , Antineoplásicos/química , Benzimidazóis/química , Linhagem Celular Tumoral , Ensaios de Seleção de Medicamentos Antitumorais , Humanos , Neoplasias/tratamento farmacológico , Quinolizidinas/química , Relação Estrutura-Atividade
16.
J Nat Prod ; 76(4): 727-31, 2013 Apr 26.
Artigo em Inglês | MEDLINE | ID: mdl-23461628

RESUMO

(+)-Laburnamine (1), a rare alkaloid extracted from Laburnum anagyroides seeds (∼4 mg from 1 kg), was shown to bind with high affinity (Ki, 293 nM) to the α4ß2 nicotinic receptor subtype, which is, respectively, 126 and 136 times higher than to the α3ß4 (Ki 37 µM) and α7 subtypes (Ki 40 µM). When its ability to release [(3)H]-dopamine from striatal slices was tested in a functional assay, compound 1 behaved as a partial agonist with an EC50 of 5.8 µM and an Emax that was 43% that of nicotine. When incubated with nicotine in the same assay, 1 prevented a maximal effect from being reached.


Assuntos
Alcaloides/farmacologia , Receptores Nicotínicos/efeitos dos fármacos , Alcaloides/química , Alcaloides/isolamento & purificação , Animais , Ligação Competitiva , Corpo Estriado/metabolismo , Dopamina/metabolismo , Relação Dose-Resposta a Droga , Humanos , Itália , Ligantes , Neostriado/metabolismo , Nicotina/metabolismo , Piridinas/metabolismo , Ratos , Ratos Sprague-Dawley , Sementes/química , Estereoisomerismo
17.
Br J Pharmacol ; 168(4): 835-49, 2013 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-22957729

RESUMO

BACKGROUND AND PURPOSE: Many of the addictive and rewarding effects of nicotine are due to its actions on the neuronal nicotinic ACh receptor (nAChR) subtypes expressed in dopaminergic mesocorticolimbic cells. The partial agonists, cytisine and varenicline, are helpful smoking cessation aids. These drugs have a number of side effects that limit their usefulness. The aim of this study was to investigate the preclinical pharmacology of the cytisine dimer1,2-bisN-cytisinylethane (CC4). EXPERIMENTAL APPROACH: The effects of CC4 on nAChRs were investigated using in vitro assays and animal behaviours. KEY RESULTS: When electrophysiologically tested using heterologously expressed human subtypes, CC4 was less efficacious than cytisine on neuronal α4ß2, α3ß4, α7 and muscle-type receptors, and had no effect on 5-hydroxytryptamine3 receptors. Acting through α4ß2 and α6ß2 nAChRs, CC4 is a partial agonist of nAChR-mediated striatal dopamine release and, when co-incubated with nicotine, prevented nicotine's maximal effect on this response. In addition, it had low affinity for, and was less efficacious than nicotine and cytisine on the α3ß4 and α7-nAChR subtypes. Like cytisine and nicotine, CC4-induced conditioned place preference (CPP), and its self-administration shows an inverted-U dose-response curve. Pretreatment with non-reinforcing doses of CC4 significantly reduced nicotine-induced self-administration and CPP without affecting motor functions. CONCLUSION AND IMPLICATIONS: Our in vitro and in vivo findings reveal that CC4 selectively reduces behaviours associated with nicotine addiction consistent with the partial agonist selectivity of CC4 for ß2-nAChRs. The results support the possible development of CC4 or its derivatives as a promising drug for tobacco smoking cessation.


Assuntos
Alcaloides/farmacologia , Azocinas/farmacologia , Agonistas Nicotínicos/farmacologia , Quinolizinas/farmacologia , Receptores Nicotínicos/metabolismo , Abandono do Uso de Tabaco , Alcaloides/química , Animais , Azocinas/química , Comportamento Animal/efeitos dos fármacos , Agonismo Parcial de Drogas , Masculino , Camundongos , Camundongos Endogâmicos C57BL , Estrutura Molecular , Atividade Motora/efeitos dos fármacos , Nicotina/administração & dosagem , Agonistas Nicotínicos/química , Ligação Proteica , Quinolizinas/química , Ratos , Ratos Wistar , Autoadministração , Tabagismo/tratamento farmacológico
18.
Antiviral Res ; 91(2): 133-41, 2011 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-21619897

RESUMO

Twenty-six 9-aminoacridine derivatives were evaluated in cell-based assays for cytotoxicity and antiviral activity against a panel of 10 RNA and DNA viruses. While seven compounds (9, 10, 14, 19, 21, 22, 24) did not affect any virus and two (6, 11) were moderately active against CVB-5 or Reo-1, 17 compounds exhibited a marked specific activity against BVDV, prototype of pestiviruses which are responsible for severe diseases of livestock. Most anti-BVDV agents showed EC(50) values in the range 0.1-8 µM, thus comparing favorably with the reference drugs ribavirine and NM 108. Some compounds, particularly those bearing a quinolizidinylalkyl side chain, displayed pronounced cytotoxicity. Further studies are warranted in order to achieve still better anti-BVDV agents, and to explore the potential antiproliferative activity of this kind of compounds.


Assuntos
Acridinas/farmacologia , Aminoacridinas/farmacologia , Antivirais/farmacologia , Vírus de DNA/efeitos dos fármacos , Vírus da Diarreia Viral Bovina/efeitos dos fármacos , Acridinas/síntese química , Acridinas/química , Aminoacridinas/química , Animais , Antivirais/síntese química , Antivirais/química , Linhagem Celular , Dimetil Sulfóxido/química , Humanos , Modelos Lineares , Testes de Sensibilidade Microbiana , Estrutura Molecular , Vírus de RNA/efeitos dos fármacos
19.
Neurotox Res ; 19(4): 556-74, 2011 May.
Artigo em Inglês | MEDLINE | ID: mdl-20405353

RESUMO

Quinacrine is one of the few molecules tested to treat patients affected by prion diseases, although the clinical outcome is largely unsatisfactory. To identify novel derivatives with higher neuroprotective activity, we evaluated the effects of a small library of acridine derivatives. The 6-chloro-2-methoxyacridine derivatives bearing on position 9 a quinolizidin-1-ylamino (Q1, Q2) or a quinolizidin-1-ylalkylamino residue (Q3, Q4, Q6, Q7), the thio-bioisoster of Q3 (Q5), the 9-(N-lupinylthiopropyl)amino derivative (Q8) and simple acridines (Q9 and Q10) were considered. We compared the effects of quinacrine and these novel analogues in the inhibition of the cytotoxic activity and protease K (PK) resistance of the human prion protein fragment 90-231 (hPrP90-231). We demonstrate that quinacrine caused a significant reduction of hPrP90-231 toxicity due to its binding to the fragment and the prevention of its conversion in a toxic isoform. All acridine derivatives analyzed showed high affinity binding for hPrP90-231, but only Q3 and Q10, caused a significant reduction of hPrP90-231 cytotoxicity, with higher efficacy than quinacrine. We attempted to correlate the cytoprotective effects of the new compounds with some biochemical parameters (binding affinity to hPrP90-231, intrinsic fluorescence quenching, hydrophobic amino acid exposure), but a direct relationship occurred only with the reduction of PK resistance, likely due to the prevention of the acquisition of the ß-sheet-rich toxic conformation. These data represent interesting leads for further modifications of the basic side chain and the substituent pattern of the acridine nucleus to develop novel compounds with improved antiprion activity to be tested in in vivo experimental setting.


Assuntos
Acridinas/farmacologia , Fragmentos de Peptídeos/antagonistas & inibidores , Fragmentos de Peptídeos/toxicidade , Príons/antagonistas & inibidores , Príons/toxicidade , Quinacrina/farmacologia , Acridinas/química , Animais , Animais Recém-Nascidos , Morte Celular/efeitos dos fármacos , Morte Celular/fisiologia , Linhagem Celular Tumoral , Células Cultivadas , Cerebelo/efeitos dos fármacos , Cerebelo/patologia , Humanos , Quinacrina/análogos & derivados , Ratos , Ratos Sprague-Dawley , Resultado do Tratamento
20.
J Med Chem ; 53(12): 4668-77, 2010 Jun 24.
Artigo em Inglês | MEDLINE | ID: mdl-20509610

RESUMO

Fifteen quinolizidine derivatives have been tested for antiarrhythmic, inotropic, and chronotropic effects on isolated guinea pig (gp) heart tissues and to assess calcium antagonist activity. All compounds exhibited from moderate to high antiarrhythmic activity, and five of them (3, 4, 6, 13, and 15) were more active and potent than the reference drugs (amiodarone, lidocaine, procainamide, and quinidine). These compounds were studied on spontaneously beating Langendorff-perfuse gp heart; even at concentration 17-67 times higher than the corresponding EC(50) for antiarrhythmic activity, they prolonged the QT intervals only moderately, comparing favorably with amiodarone and quinidine. Compounds 3 and 15 deserve further investigation due to their interesting cardiovascular profiles.


Assuntos
Antiarrítmicos/síntese química , Quinolizidinas/síntese química , Animais , Antiarrítmicos/química , Antiarrítmicos/farmacologia , Bloqueadores dos Canais de Cálcio/síntese química , Bloqueadores dos Canais de Cálcio/química , Bloqueadores dos Canais de Cálcio/farmacologia , Estimulação Elétrica , Cobaias , Coração/efeitos dos fármacos , Coração/fisiopatologia , Frequência Cardíaca/efeitos dos fármacos , Íleo/efeitos dos fármacos , Íleo/fisiologia , Técnicas In Vitro , Músculo Liso/efeitos dos fármacos , Músculo Liso/fisiologia , Contração Miocárdica/efeitos dos fármacos , Inibidores da Agregação Plaquetária/síntese química , Inibidores da Agregação Plaquetária/química , Inibidores da Agregação Plaquetária/farmacologia , Quinolizidinas/química , Quinolizidinas/farmacologia , Receptor Muscarínico M2/fisiologia , Estereoisomerismo , Relação Estrutura-Atividade , Vasodilatadores/síntese química , Vasodilatadores/química , Vasodilatadores/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...